Table of Content

Open Access iconOpen Access

ARTICLE

Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction

Shoumiao Li*†, Baozhong Li, Jiaxiang Wang*, Da Zhang*, Zhiqiang Liu, Zhizhong Zhang, Wei Zhang, Yunjie Wang, Dongxiao Bai, Jianyun Guan, Yong Zhang

* Department of Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P.R. China
† Department of Surgery, Anyang Tumor Hospital, Anyang, Henan, P.R. China

Oncology Research 2017, 25(1), 93-97. https://doi.org/10.3727/096504016X14719078133564

Abstract

The identification of reliable predictors of chemotherapy sensitivity and early screening of adenocarcinoma of gastroesophageal junction (AGEJ) patients who are resistant to chemotherapy has become an important area of clinical and translational research. We aimed to investigate the predictive value of seven cancerassociated cellular proteins for neoadjuvant chemotherapy in AGEJ patients. Clinical data of 93 patients who received neoadjuvant chemotherapy for locally advanced AGEJ between June 2010 and December 2014 were reviewed. All patients were administered the combination regimen of S-1 and oxaliplatin (SOX). Expression of P-glycoprotein (P-gp), glutathione S-transferase-p (GST-π), topoisomerase II (topo II), multidrug resistance gene-associated protein (MRP), lung resistance-related protein (LRP), Ki-67, and p53 was determined by immunohistochemistry (IHC) in AGEJ tissues before neoadjuvant chemotherapy. Chemotherapeutic efficacy was evaluated according to RECIST 1.0 standards and histopathological results, and the relationship between the expression of the cellular proteins and chemotherapy efficacy was analyzed. The SOX regimen was associated with an overall response rate of 46.2%. The frequency of expression of the seven cancer-associated factors in the AGEJ tissues was as follows: P-gp, 64.5%; GST-π, 39.8%; topo II, 72.0%; MRP, 33.3%; LRP, 68.8%; Ki-67, 62.4%; and p53, 40.9%. Expression of Ki-67 (p = 0.003) and p53 (p = 0.009) was significantly correlated with chemotherapy sensitivity. Elevated Ki-67 expression and decreased p53 expression predict for SOX insensitivity in AGEJ, and the cellular expression of these respective proteins may provide a useful reference for designing individualized chemotherapy regimens for AGEJ patients in the future.

Keywords


Cite This Article

APA Style
Li, S., Li, B., Wang, J., Zhang, D., Liu, Z. et al. (2017). Identification of sensitivity predictors of neoadjuvant chemotherapy for the treatment of adenocarcinoma of gastroesophageal junction. Oncology Research, 25(1), 93-97. https://doi.org/10.3727/096504016X14719078133564
Vancouver Style
Li S, Li B, Wang J, Zhang D, Liu Z, Zhang Z, et al. Identification of sensitivity predictors of neoadjuvant chemotherapy for the treatment of adenocarcinoma of gastroesophageal junction. Oncol Res. 2017;25(1):93-97 https://doi.org/10.3727/096504016X14719078133564
IEEE Style
S. Li et al., "Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction," Oncol. Res., vol. 25, no. 1, pp. 93-97. 2017. https://doi.org/10.3727/096504016X14719078133564



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 60

    View

  • 49

    Download

  • 0

    Like

Share Link